ReviewMolecular biomedicine2026
Inflammatory bowel diseases: pathological mechanisms and therapeutic perspectives.
Review in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Water-triggered in-situ gelling phospholipid oil enema for enhanced budesonide delivery and mucosal healing in ulcerative colitis.International journal of pharmaceutics: X · 2026Article
- Microbiome-Derived Tryptophan Metabolites Regulate AhR Signaling to Restore Epithelial Barrier Integrity in Inflammatory Bowel Disease.MicrobiologyOpen · 2026Review
- Macrophage SELENOP controls neutrophil homeostasis through redox stress regulation in Crohn's disease.Redox biology · 2026Article
- Psychological adaptation and health-related quality of life in inflammatory bowel disease: a 5-year follow-up study.Research in psychotherapy (Milano) · 2026Article
- Phytotherapeutic potential of Gossypium barbadense L. root as an alternative therapy for colitis: a comprehensive review with network pharmacology insights.Inflammopharmacology · 2026Review
- Oral hydrogel systems in lower gastrointestinal disorders: From disease-based therapy to microbiota-guided design.Materials today. Bio · 2026Review
- From metabolic node to smart building block: α-Ketoglutarate-empowered biomaterials for programmable cell fate.Materials today. Bio · 2026Review
- Transcriptomic Analysis Reveals the Antioxidant and Anti-Inflammatory Mechanisms of EGCG-Zn Nanoparticles in Dextran Sulfate Sodium-Induced Colitis in Mice.Antioxidants (Basel, Switzerland) · 2026Article
- Role of Fatty Acid Oxidation in Crohn's Disease and Ulcerative Colitis: Metabolomics Analysis and Experimental Evidence.Cell biochemistry and function · 2026Article
- Integrative transcriptomic analysis unveils FXR as a key regulator of intestinal stemness and inflammation in ulcerative colitis.International journal of molecular medicine · 2026Article
- Atopic Dermatitis and Risk of Inflammatory Bowel Disease in Children: A Systematic Review and Meta-Analysis.Cureus · 2026Review
- Characteristics of the Tongue Coating Microbiome and Its Subtype Differences in Patients with Inflammatory Bowel Disease.Microorganisms · 2026Article
- Molecular determinants of thromboinflammatory activation in inflammatory bowel disease.Journal of molecular medicine (Berlin, Germany) · 2026Review
- Article
- Berberine in Inflammatory Bowel Disease: Integrative Regulation of the Microbiota-Immune-Barrier Axis.International journal of molecular sciences · 2026Review
- Temporal transcriptomic profiling identifies core regulators in cytokine-induced gut barrier disruption in differentiated Caco-2 cells.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Article
- Pro-Inflammatory Cytokines as Core Mediators of Colonic Epithelial Barrier Dysfunction: Roles of TNF-α, IFN-γ, IL-1β, and IL-6.International journal of molecular sciences · 2026Review
- Dried Ginger Milk Extract Alleviates Inflammatory Bowel Disease-Associated Bone Loss via Gut Microbiota-Metabolite Remodeling and MEK/ERK Inhibition.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Therapeutic Potential of Kinkeliba (Molecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Inflammatory bowel disease (IBD) is a heterogeneous group of disorders characterized primarily by chronic relapsing intestinal inflammation, encompassing Crohn's disease (CD) and ulcerative colitis (UC), affecting individuals across age groups with variable clinical manifestations. With the advancement of global industrialization, its incidence continues to rise, particularly in newly industrialized regions, which not only severely impairs patients' quality of life but also emerges as a major public health concern threatening digestive system health, accompanied by a substantial healthcare burden, thus necessitating the development of more effective and safer individualized treatment strategies. This review summarizes the pathogenesis of IBD, including intestinal mucosal immune dysregulation, intestinal barrier damage, gut microbiota dysbiosis, reactive oxygen species (ROS) homeostasis imbalance, and the complex crosstalk between genetic and environmental factors; however, clinical treatment still faces numerous challenges: 30%-40% of patients exhibit primary or secondary non-response to existing therapeutic regimens such as biologics and small-molecule drugs, and prolonged administration tends to induce significant side effects. Further integrated herein are emerging strategies such as ROS modulators, novel immune-targeted modulation, intestinal barrier repair agents, microbiota-directed interventions, multi-omics-based precision medicine, and artificial intelligence (AI)-assisted therapy, which represent key directions to address the limitations of traditional treatments. This article begins with an overview of basic pathological mechanisms and offers a comprehensive overview of relevant therapeutic approaches and future development directions, aiming to facilitate the transition of the field from traditional generalized therapies to personalized precision medicine and to bridge the long-standing gap between basic research and clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.